Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
This is the capstone module: a complete behavioral interview prep framework for Cencora. Candidates will walk away with a 5-story preparation checklist, each story explicitly mapped to Cencora's six guiding principles, plus concrete language for the highest-stakes question of all — "Why Cencora?". This module synthesizes everything from Modules 1-9 into a working interview playbook.
Forget guessing what the Cencora interview is like — this module walks through the real process based on hundreds of candidate reports: recruiter screen → hiring manager → panel → VP, ~24-day average timeline, 30-minute behavioral rounds, and the questions candidates report being asked most often. This is the most tactical module in the series.
In February 2024, Cencora suffered a cyberattack that ultimately affected 1.43 million people and led to a $40 million settlement. In 2025, its directors agreed to a $111 million opioid governance settlement. This module unpacks how Cencora has framed crisis, trust, and resilience — and how candidates can speak about integrity, accountability, and crisis response in interviews without sounding like they're criticizing the company.
Three companies — Cencora, McKesson, and Cardinal Health — control 90-95% of U.S. drug distribution. This module gives candidates a clear, defensible take on how Cencora differentiates from its rivals, so they can answer "Why Cencora over McKesson?" without sounding rehearsed or hostile.
Cencora isn't a tech company — but technology is the through-line of CEO Bob Mauch's strategy, and Pawan Verma was hired in November 2024 specifically to accelerate that work. This module covers what Cencora's tech organization actually does, the AI and data initiatives in flight, and how technical candidates should frame their experience to land at a Fortune 11 healthcare company.
The single most important strategic story at Cencora today is the pivot from commodity drug wholesaling to specialty pharmaceuticals, capped by the $4.4 billion acquisition of Retina Consultants of America in January 2025. This module helps candidates understand vertical integration into physician practices, why specialty matters, and how to talk about it credibly in an interview.
Bob Mauch became CEO of Cencora in October 2024, and his strategic priorities now define what every team is being measured against. This module covers Mauch's background, his four strategic drivers, the $1 billion U.S. distribution network expansion announced in November 2025, and how candidates can speak intelligently about where Cencora is going under his leadership.
Most candidates walk into Cencora interviews with a vague idea that "they distribute drugs" — and then fumble when asked specifics. This module gives candidates a working mental model of Cencora's business: U.S. wholesale, specialty distribution, MSO physician practices, World Courier global logistics, Alliance Healthcare in Europe, and the new segment structure announced in 2025.
Cencora doesn't have "Leadership Principles" the way Amazon does — but its six guiding principles function as the de facto evaluation framework in interviews. This module breaks down each principle, what it actually means at Cencora, and exactly how to mirror this language in behavioral answers without sounding rehearsed.
On August 30, 2023, a 22-year-old name disappeared from the New York Stock Exchange when AmerisourceBergen (NYSE: ABC) became Cencora, Inc. (NYSE: COR). This module unpacks why the company changed its name, what "Cencora" actually means, and how candidates can use the rebrand story to demonstrate they understand the company's strategic direction — not just its history.